Seeking Alpha

The FDA accepts Edap's (EDAP +9.5%) pre-market approval application for its ultrasound device...

The FDA accepts Edap's (EDAP +9.5%) pre-market approval application for its ultrasound device for treating low-risk, localized prostate cancer. The next step for the product, which is called the Ablatherm Integrated Imaging HIFU (High Intensity Focused Ultrasound), is the filing review. Both assessments look at the completeness of the application and not the clinical outcomes of the study. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector